31 articles found
Browse Rainier Rehab's editorial coverage of Substance-use-disorder. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new substance-use-disorder reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
University of Arkansas Medical Sciences convenes statewide summit as data reveals 60% of adolescents in substance use treatment have co-occurring mental illness.
Single dose of psilocybin with therapy support produced rapid, sustained reductions in suicidal thoughts among treatment-resistant patients
New research reveals how cAMP signaling in brain neurons drives GLP-1 weight loss effects, opening pathways to enhance addiction treatments.
University of Reading study finds single psilocybin dose reduces neuropathic pain for weeks and makes standard painkillers work better.
Research published in the American Journal of Preventive Medicine reveals rising barriers to timely care for adolescents with cannabis use disorder, with younger teens and males most affected.
University of Cincinnati study demonstrates that embedding addiction treatment into primary care residency training expands patient access and boosts physician confidence in treating SUDs.
MSDH becomes one of few state health departments offering direct clinic-based SUD care, using technology to identify risk earlier and reduce barriers.
New NIH-funded research shows oral GLP-1 drugs like orforglipron reach the central amygdala, opening potential pathways for treating substance use disorders.
Research identifies novel mechanism where oral GLP-1 medications penetrate deep into brain's reward center, opening potential pathways for treating addiction
JAMA study finds psychedelic-assisted therapy produced higher abstinence rates and longer relapse prevention than standard treatment
University of Kentucky researchers find that experimental Alzheimer's medication MW150 could reduce brain inflammation and neural damage during alcohol withdrawal, potentially lowering relapse rates.
New federal data shows 84% of Americans who needed addiction treatment in 2025 got none, as stigma and training gaps keep doctors on the sidelines.
University of Chicago researchers investigate why isolation during teenage years may permanently alter brain development and increase vulnerability to substance use disorders.
SAMHSA's 2025 National Survey on Drug Use and Health shows fewer adolescents and young adults using alcohol, tobacco, marijuana, and other drugs.
New BMJ Open research finds semaglutide and tirzepatide associated with reduced alcohol-related emergency visits among adults with alcohol use disorder.
Arizona State University researchers find opioid withdrawal suppresses two myelin-regulating genes in the prefrontal cortex, pointing to a new treatment target.
University of Maryland researcher secures federal grant to expand school-based addiction treatment access in underserved rural communities
New research from USC Keck Medicine reveals heavy marijuana smokers face 3.5 to 5 times higher risk of lung and head and neck cancers, raising questions as cannabis legalization expands.
KFF's new tracker reveals how the second Trump administration is reshaping federal mental health and substance use policy through law-and-order approaches and treatment-focused initiatives.
European Heart Journal Open proposes neurocardiometabolic framework linking addiction treatment with cardiovascular care through GLP-1 receptor therapies
APA's July 2026 journal issues highlight emerging evidence for digital health tools and telehealth in treating substance use disorders in underserved communities
State awards opioid settlement funds to 12 organizations working to prevent substance use among school-aged children across Michigan.
Missouri county announces distribution of opioid settlement money to nine local organizations for prevention, treatment, and recovery services.
Cabarrus County has no teen substance use treatment services. New state funding aims to change that as overdose ER visits jump 67%.
Five rural Arizona sheriff's offices will receive $2 million each to expand reentry services for formerly incarcerated individuals battling addiction.
New TOPS initiative replaces scare tactics with evidence-based behavioral change strategies, video games, and graphic novels created by teens
UC San Diego researchers identify liver-based genetic markers for cocaine addiction, opening new avenues for medication development beyond brain-targeting approaches.
Eight new grant programs target child trauma, suicide prevention, and workforce development as part of the Great American Recovery Initiative.
A new federal Request for Information invites patients, providers and researchers to tell HHS which addiction programs work — with comments due July 5, 2026.
State lawmakers pass bill to study psychedelic-assisted therapy, joining growing national movement to explore alternative treatments for substance use disorders and mental health conditions.
Federal scientists approve phase I study of mitragynine, opening new frontiers in opioid addiction research amid ongoing debates over kratom's safety and efficacy.